Gender effects in familial cancer

Gender effects in familial cancer
复制标题

DOI:
10.1002/ijc.10676
复制
发表时间:
2002-11-10
影响因子:
6.4
通讯作者:
Li, XJ
Li, XJ
中科院分区:
医学1区
文献类型:
--
作者:
Hemminki, K;Li, XJ

文献摘要

被引文献

相似文献

关于家族性癌症性别比例的数据非常有限。这些数据将是有价值的性染色体的影响和背景和家族率之间的相互作用的评估。我们使用全国范围内的瑞典家庭癌症数据库对1020万人和超过100万肿瘤进行分析,通过父亲和母亲的一致性癌症来分析男性和女性后代的家族风险。家族性癌症的性别比来自男性和女性共有的15个癌症部位。在14个地点的性别比(男性/女性)的家族相对风险范围在0.78和1.41之间,没有性别偏好的证据,这表明性染色体并没有在很大程度上有助于家族风险。此外,在背景发病率因性别而差异很大的癌症中,如膀胱癌(性别比2.82)和非甲状腺内分泌肿瘤(0.65),家族效应与背景发病率成比例,家族性别比接近1。在甲状腺癌中,家族性性别比为2.48(1.54-3.98),背景发病比为0.31。这是第一个证明原发性癌症中性别比例相反的证据,即,低背景风险的性别有较高的家族风险。高家族比率为2.85(95%CI:1.35-6.03),是由于甲状腺腺癌,包括乳头状和滤泡型。(C)2002 Wiley-Liss,Inc.
Very limited data are available on sex ratios in familial cancer. Such data would be valuable in the assessment of sex chromosome effects and of interactions between background and familial rates. We used the nationwide Swedish Family-Cancer Database on 10.2 million individuals and over 1 million neoplasms to analyze familial risks for male and female offspring by paternal and maternal concordant cancer. Sex ratios for familial cancer were derived for cancer at 15 sites shared by men and women. At 14 sites the sex ratio (male/female) for familial relative risk ranged between 0.78 and 1.41, with no evidence of sex preference, suggesting that sex chromosomes do not contribute to a noticeable extent to familial risks. Furthermore, in cancers where the background incidence varied extensively by sex, such as bladder cancer (sex ratio 2.82) and nonthyroid endocrine tumors (0.65), the familial effect was proportionate to the background incidence and the familial sex ratio was close to unity. In thyroid cancer, the familial sex ratio was 2.48 (1.54-3.98) and the background incidence ratio was 0.31. This was the first evidence of an inverse sex ratio in primary cancer, i.e., higher familial risk in the gender of low background risk. The high familial ratio, 2.85 (95% Cl: 1.35-6.03), was due to thyroid adenocarcinoma, encompassing both papillary and follicular types. (C) 2002 Wiley-Liss, Inc.